export const bromhexinEfedrin = {
	id: 24,
	otcDrug: false,
	categories: "Cough",
	class: "2",
	activeSubstance: "Bromhexine, Efedrin",
	timeLimit: true,
	maxPeriod: "Not for long-term treatment",
	interactionExists: true,
	name: "Mollipect",
	dosage: "0,5 mg/ml + 1 mg/ml",
	quantity: "300ml",
	drugGroup: "Expectorant, bronchodilating,mucolytics",
	imageUrl:
		"data:image/jpeg;base64,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 ",
	dosing: {
		adults: "Adults and children over 15 years of age: 15 ml 3-4 times per day",
		children:
			"(11-14 years):10-15 ml 3 times a day,  (6-10 years):10 ml 3 times a day,  (2-5 years):5 ml 3 times per day,  (Children from 6 months): 2.5 ml 3 times per day  ",
	},
	maxDose: "60ml",
	withMeal: false,
	betweenMeals: false,
	infants: false,
	adults: true,
	minAge: "6 months",
	pregnancy:
		"Available preclinical studies as well as clinical experience have not provided any evidence of adverse effects during pregnancy. However, normal caution should be observed when using medicines during pregnancy, especially during the first trimester.",
	breastfeeding:
		"Bromhexine probably excreted in breast milk and should therefore be avoided during breastfeeding ",
	indications: [
		"Cough with tenacious phlegm and simultaneous need for a bronchodilating effect.",
	],
	contraindications: [
		"Hypersensitivity to loperamide hydrochloride or to any excipient",
	],
	pharmacodynamics:
		"Active substances in Mollipect are bromhexine and ephedrine (Adrenaline). Bromhexine is considered to have an expectorant and mucolytic effect, (dissolves tenacious secretions).It can facilitate expectoration of mucus. Ephedrine has a bronchodilating and mucosal decongestant effect",

	description:
		"Bromhexine is used for phlegm cough and widens the airways at the same time so that it becomes easier to breathe .Bromhexine contains ethanol and a dose of 2.5 ml of this medicine given to a child weighing 8 kg gives an exposure of 6 mg/kg of ethanol which can cause an elevated blood alcohol concentration ",
	interactions: [
		{
			name: "Moklobemid",
			activeSubstance: "Moklobemid",
			drugGroup: ["MAO inhibitors"],
			prescriptionDrug: true,
			indications: ["Depression"],
			interactionType: "C",
			consequence:
				"Case reports have been reported with severe headache, pronounced increase in blood pressure and occasional cases of subarachnoid haemorrhage. The reason is ephedrine's indirect effect on the central nervous release of adrenergic signaling substances",
			suggestions: "Combination should be avoided",
		},
		{
			name: "Selegiline",
			activeSubstance: "Selegiline",
			drugGroup: ["MAO inhibitors"],
			prescriptionDrug: true,
			indications: ["Parkinson's disease"],
			interactionType: "C",
			consequence:
				"Case reports have been reported with severe headache, pronounced increase in blood pressure and occasional cases of subarachnoid haemorrhage. The reason is ephedrine's indirect effect on the central nervous release of adrenergic signaling substances",

			suggestions: "Combination should be avoided",
		},
		{
			name: "Patients with several different antihypertensive medications",
			activeSubstance: "",
			drugGroup: ["Antihypertensive"],
			prescriptionDrug: true,
			indications: ["High blood pressure"],
			interactionType: "C",
			consequence:
				"Patients on several different antihypertensive medications have impaired vasomotor control and are therefore more sensitive to substances with vasoconstrictive properties such as ephedrine.",
			suggestions:
				"Combination should be avoided, alternatively it may be necessary to adjust the dosage of the medications",
		},
	],
	sideEffects: [
		"Dizziness",
		"headache",
		"tremors",
		"itching",
		"skin rash",
		"palpitations",
		"anxiety",
	],
};
